Neoadjuvant Immuno-Chemotherapy Versus Neoadjuvant Chemoradiotherapy in Locally Advanced Oesophageal Squamous Cell Carcinoma
NICE offers better survival than CROSS with similar recurrence patterns. Adjuvant immunotherapy might be an important factor for long-term benefits in residual pathological disease after NICE.
Authors
- Zhigang Li (ORCID: https://orcid.org/0000-0001-5086-5334)
- Chang Yuan (ORCID: https://orcid.org/0000-0002-4744-1642)
- Jun Liu (ORCID: https://orcid.org/0000-0003-2011-3961)
- Bin Li (ORCID: https://orcid.org/0009-0008-3791-0936)
- Yuchen Han (ORCID: https://orcid.org/0000-0001-5610-9150)
- Yang Yang (ORCID: https://orcid.org/0000-0001-5720-773X)
- Ming Zhang (ORCID: https://orcid.org/0000-0003-0151-7813)
- Zhichao Liu (ORCID: https://orcid.org/0000-0003-3542-0905)
- Chunguang Li (ORCID: https://orcid.org/0000-0003-3249-4087)
- Yuxin Yang (ORCID: https://orcid.org/0000-0001-7398-7473)
Institutions
- Shanghai Jiao Tong University (CN)
- Shanghai Chest Hospital (CN)
Publication Details
- Journal
- European Journal of Cardio-Thoracic Surgery
- Published
- 2025-09-19
- DOI
- https://doi.org/10.1093/ejcts/ezaf302
- Citations
- 2
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.01